Metropolitan Life Insurance Company (MetLife)’s Tourmaline Bio TRML Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-162	Closed	-$7.29K	–	2355
2022 Q2	$7.29K	Buy	+162	New	+$12.8K	﹤0.01%	2329
2022 Q1	–	Sell	-723	Closed	-$111K	–	2667
2021 Q4	$111K	Buy	+723	New	+$107K	﹤0.01%	2421

Other funds holding TRML

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s TRML Position: Q3 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Tourmaline Bio (TRML) in Q3 2022, closing a stake of 162 shares — an estimated $7.29K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TRML in Q4 2021 and held it in 2 quarters. The position peaked at $111K in Q4 2021. 56 funds tracked by Wall St. Rank hold TRML as of Q3 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining Tourmaline Bio position as of Q3 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 162 Tourmaline Bio shares in Q3 2022, an estimated $7.29K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Tourmaline Bio in Q4 2021 and held it in 2 quarters.
Metropolitan Life Insurance Company (MetLife)'s Tourmaline Bio position peaked at $111K in Q4 2021.
56 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2022, filed 14 Nov 2022.